Lista de obras -

2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders

artículo científico publicado en 2020

Achieving target low‑density lipoprotein cholesterol levels in the Polish population

scientific article published on 01 January 2012

Chapter 9 Interaction of Polyene Macrolide Antibiotics with Lipid Model Membranes

Clinical management of heterozygous familial hypercholesterolemia in a Polish outpatient metabolic clinic: a retrospective observational study

scientific article published on 30 November 2017

Combination pharmacotherapy therapy in the management of atherogenic dyslipidemia

artículo científico publicado en 2005

Comparative in vitro studies on liposomal formulations of amphotericin B and its derivative, N-methyl-N-D-fructosyl amphotericin B methyl ester (MFAME).

artículo científico publicado en 2002

Current state-of-the-art knowledge on the role of omega-3 fatty acids in the prevention of cardiovascular disease

artículo científico publicado en 2020

Facilitated diffusion of glucosamine-6-phosphate synthase inhibitors enhances their antifungal activity

artículo científico publicado en 2002

Homocysteine--is it still an important risk factor for cardiovascular disease?

artículo científico

How do we know that statins are diabetogenic, and why? Is it an important issue in the clinical practice?

scientific article published on 01 August 2018

How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors

artículo científico publicado en 2020

Interaction of amphotericin B and its low toxic derivative, N-methyl-N-D-fructosyl amphotericin B methyl ester, with fungal, mammalian and bacterial cells measured by the energy transfer method

artículo científico publicado en 2004

Landmark studies in coronary heart disease epidemiology. The Framingham Heart Study after 70 years and the Seven Countries Study after 60 years

artículo científico publicado en 2019

Management of familial heterozygous hypercholesterolemia. Position paper of the Polish Lipid Expert Forum

scientific article published on 01 January 2013

Management of familial heterozygous hypercholesterolemia. Position paper of the Polish Lipid Expert Forum

artículo científico publicado en 2013

Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum

artículo científico publicado en 2013

Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum

artículo científico

PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.

scientific article published on 19 December 2016

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

artículo científico publicado en 2021

Polish Forum for Prevention Guidelines on Dyslipidaemia: update 2016

artículo científico publicado en 2017

Polish Forum for Prevention Guidelines on cardiovascular diseases prevention in children and adolescents

artículo científico publicado en 2010

Polish forum for prevention guidelines on dyslipidaemia

artículo científico publicado en 2008

Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey

artículo científico publicado en 2016

Prevalence, diagnosis, and treatment of familial hypercholesterolaemia in outpatient practice in Poland

artículo científico publicado en 2018

Prevention of ischaemic heart disease in the elderly. Reduction of coronary risk factors

artículo científico publicado el 1 de abril de 2003

Primary prevention of cardiovascular disease and other chronic noncommunicable diseases in the centre of attention of the United Nations: special importance of a prudent diet.

artículo científico publicado en 2013

Recommendation for the management of dyslipidemia in Poland - Third Declaration of Sopot. Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy

artículo científico publicado en 2018

Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement

artículo científico publicado en 2016

Stanowisko dotyczące postępowania w rodzinnej hipercholesterolemii u dzieci i młodzieży. Stanowisko Forum Ekspertów Lipidowych

artículo científico publicado en 2013

Statins 25 years in preventive cardiology

artículo científico publicado el 1 de enero de 2012

Studies of the effects of antifungal cationic derivatives of amphotericin B on human erythrocytes

artículo científico publicado en 2004

The HDL paradox: what does it mean and how to manage low serum HDL cholesterol level?

artículo científico

The mechanism of overcoming multidrug resistance (MDR) of fungi by amphotericin B and its derivatives

scientific article published on 01 July 2007

Treatment of dyslipidemia

artículo científico publicado en 2002

Treatment of lipid disorders in metabolic syndrome and type 2 diabetes. The place for fibrates

artículo científico publicado en 2005

Visfatin--what is currently known about its role in physiology and pathology?

artículo científico publicado el 1 de enero de 2011

What do we know about lipoprotein(a)?

artículo científico

What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?

scientific article published on 08 April 2020

What does obesity paradox mean in coronary heart disease?

artículo científico publicado en 2013

What is the future for niacin after the AIM-HIGH study?

artículo científico publicado el 1 de enero de 2012

[Actual problems of dyslipidaemia treatment in Poland - 2nd Declaration of Sopot. Experts' Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy]

artículo científico publicado en 2014

[Effectiveness of omega 3 fatty acids in ischaemic heart disease prevention]

artículo científico publicado en 2005

[Evaluation of the coronary risk: is it enough to asses ApoB/ApoA1 ratio only or is plasma lipoprotein concentration still necessary?]

scientific article published on 01 February 2005

[Low-carbohydrate, high-fat diets: efficacy and safety]

artículo científico publicado en 2004

[Management in familial hypercholesterolaemia in children and adolescents. Position of the Lipid Expert Forum]

artículo científico publicado en 2013

[Management of familial heterozygous hypercholesterolaemia. Position paper of the Polish Lipid Expert Forum]

scientific article published on 01 January 2013

[Metabolic syndrome as a coronary risk factor. Prevention and treatment]

scientific article published on 01 July 2003

[New European guidelines on cardiovascular disease prevention in relation to the situation in Poland]

artículo científico publicado en 2004

[Safety of hypolipemic agents]

scientific article published on 01 October 2002

[Why fast food should be forbidden in Polish schools?]

artículo científico publicado en 2009

Lista de obras de

2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders

Achieving target low‑density lipoprotein cholesterol levels in the Polish population

Chapter 9 Interaction of Polyene Macrolide Antibiotics with Lipid Model Membranes

Clinical management of heterozygous familial hypercholesterolemia in a Polish outpatient metabolic clinic: a retrospective observational study

Combination pharmacotherapy therapy in the management of atherogenic dyslipidemia

Comparative in vitro studies on liposomal formulations of amphotericin B and its derivative, N-methyl-N-D-fructosyl amphotericin B methyl ester (MFAME).

Current state-of-the-art knowledge on the role of omega-3 fatty acids in the prevention of cardiovascular disease

Facilitated diffusion of glucosamine-6-phosphate synthase inhibitors enhances their antifungal activity

Homocysteine--is it still an important risk factor for cardiovascular disease?

How do we know that statins are diabetogenic, and why? Is it an important issue in the clinical practice?

How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors

Interaction of amphotericin B and its low toxic derivative, N-methyl-N-D-fructosyl amphotericin B methyl ester, with fungal, mammalian and bacterial cells measured by the energy transfer method

Landmark studies in coronary heart disease epidemiology. The Framingham Heart Study after 70 years and the Seven Countries Study after 60 years

Management of familial heterozygous hypercholesterolemia. Position paper of the Polish Lipid Expert Forum

Management of familial heterozygous hypercholesterolemia. Position paper of the Polish Lipid Expert Forum

Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum

Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum

PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

Polish Forum for Prevention Guidelines on Dyslipidaemia: update 2016

Polish Forum for Prevention Guidelines on cardiovascular diseases prevention in children and adolescents

Polish forum for prevention guidelines on dyslipidaemia

Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey

Prevalence, diagnosis, and treatment of familial hypercholesterolaemia in outpatient practice in Poland

Prevention of ischaemic heart disease in the elderly. Reduction of coronary risk factors

Primary prevention of cardiovascular disease and other chronic noncommunicable diseases in the centre of attention of the United Nations: special importance of a prudent diet.

Recommendation for the management of dyslipidemia in Poland - Third Declaration of Sopot. Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy

Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement

Stanowisko dotyczące postępowania w rodzinnej hipercholesterolemii u dzieci i młodzieży. Stanowisko Forum Ekspertów Lipidowych

Statins 25 years in preventive cardiology

Studies of the effects of antifungal cationic derivatives of amphotericin B on human erythrocytes

The HDL paradox: what does it mean and how to manage low serum HDL cholesterol level?

The mechanism of overcoming multidrug resistance (MDR) of fungi by amphotericin B and its derivatives

Treatment of dyslipidemia

Treatment of lipid disorders in metabolic syndrome and type 2 diabetes. The place for fibrates

Visfatin--what is currently known about its role in physiology and pathology?

What do we know about lipoprotein(a)?

What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?

What does obesity paradox mean in coronary heart disease?

What is the future for niacin after the AIM-HIGH study?

[Actual problems of dyslipidaemia treatment in Poland - 2nd Declaration of Sopot. Experts' Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy]

[Effectiveness of omega 3 fatty acids in ischaemic heart disease prevention]

[Evaluation of the coronary risk: is it enough to asses ApoB/ApoA1 ratio only or is plasma lipoprotein concentration still necessary?]

[Low-carbohydrate, high-fat diets: efficacy and safety]

[Management in familial hypercholesterolaemia in children and adolescents. Position of the Lipid Expert Forum]

[Management of familial heterozygous hypercholesterolaemia. Position paper of the Polish Lipid Expert Forum]

[Metabolic syndrome as a coronary risk factor. Prevention and treatment]

[New European guidelines on cardiovascular disease prevention in relation to the situation in Poland]

[Safety of hypolipemic agents]

[Why fast food should be forbidden in Polish schools?]

What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?